Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Condition(s):Hodgkin DiseaseLast Updated:February 12, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Hodgkin DiseaseLast Updated:February 12, 2019Completed
Condition(s):Graft Versus Host DiseaseLast Updated:June 27, 2013Withdrawn
Condition(s):LymphomaLast Updated:November 27, 2019Terminated
Condition(s):LymphomaLast Updated:November 4, 2020Recruiting
Condition(s):Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic MastocytosisLast Updated:January 29, 2019Completed
Condition(s):Recurrent Classic Hodgkin LymphomaLast Updated:December 17, 2020Not yet recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:June 11, 2018Terminated
Condition(s):Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell LymphomaLast Updated:August 7, 2020Active, not recruiting
Condition(s):LymphomaLast Updated:October 17, 2018Terminated
Condition(s):PTLD; Lymphoid Tumor; Hematopoietic/Lymphoid Cancer; Plasmacytic Hyperplasia PTLD; Infectious Mononucleosis; Florid Follicular Hyperplasia PTLD; Polymorphic PTLD; Monomorphic PTLD; Classical Hodgkin Lymphoma Type PTLDLast Updated:August 13, 2020Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.